SPHK1 and pulmonary arterial hypertension: Therefore, it will be necessary to produce compounds that lack inhibitory activity against ceramide synthase (active in both the de novo ceramide synthesis pathway and also in the sphingolipid rheostat) in order to execute the effect of inhibiting SK1 on hypertrophy in PAH.